Gilead agreed to acquire Arcellx in a definitive deal valuing the company at roughly $7.8 billion to secure full control of anito‑cel, a BCMA‑directed CAR‑T therapy nearing regulatory review. The acquisition consolidates development and commercialization rights that Gilead had previously shared with Arcellx and its Kite unit, eliminating profit‑sharing and milestone complexity that could slow launch execution. The deal tops up Gilead’s cell‑therapy portfolio as anito‑cel approaches a potential U.S. approval supported by pivotal Phase II data and a Biologics License Application under FDA review. Gilead said the acquisition positions it to move rapidly on launch planning and potential label expansion, while Arcellx investors gain an immediate premium and contingent value rights tied to sales milestones. Analysts project the transaction will accelerate Gilead’s ability to compete with existing BCMA CAR‑T products and to integrate Arcellx’s D‑Domain platform into next‑generation cell therapies. The move also reduces financial and operational risk for Arcellx during a critical commercial inflection point, shifting execution responsibility to an established cell‑therapy commercial organization.